REOLYSIN® is currently being manufactured under a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation. SAFC will manufacture all necessary product through the completion of clinical testing, as well as commercial product subject to the receipt of regulatory approval.
Intellectual Property Portfolio
To date Oncolytics has been issued over three hundred patents worldwide, including the US and Canada, and has more than two hundred pending applications. Issued patent claims pertaining to the reovirus cover:
Compositions of matter comprising reovirus
Pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases
Combination therapy with radiation, chemotherapy and/or immune suppressants
Methods for manufacturing reovirus and screening for susceptibility to reovirus
Pharmaceutical use of reoviruses in transplantation procedures
The Market
The American Cancer Society estimates there will be more than 1.6 million new cancer cases diagnosed in the United States alone in 2012; more than 1,500 people a day are expected to die from the disease. The US National Institutes of Health (NIH) estimates that in 2007 the direct medical costs (total of all health expenditures) associated with cancer were in excess of $100 billion.
To date, REOLYSIN® has shown activity in a broad range of cancers. Oncolytics is currently conducting clinical trials in six of the ten most common cancers diagnosed in men and five of the ten most diagnosed in women.
ONCY 07/06/2015
--Report More Than Doubling in One-Year Survival and Nearly Five-Fold Increase in Two-Year Survival as Compared to Historical Controls-- "This is the second cancer where we have confirmed that PD-L1 is upregulated in target tumors following our collaborators initial observations of PD-L1 upregulation in glioblastoma," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are currently analyzing archived samples from other completed studies and current samples from ongoing studies to determine if this is a common effect to most cancers. A systemic viral therapy that generally led to upregulation of PD-L1 would allow increased use of anti PD-L1 drugs in cancers where there is insufficient PD-L1 to make therapy possible."
Zurück
